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Abstract
Purpose – The growing success of open innovation practices in many ﬁrms raises the question of whether
such principles can be transferred for reinventing public sector organisations. A paradigm based on
principles of integrated collaboration, co-created shared value, cultivated innovation ecosystems, unleashed
exponential technologies and extraordinarily rapid adoption is the so-called Open Innovation 2.0. The
development of this approach reﬂects the perception that the innovation process has evolved. This study aims
to explore new ways to study healthcare networks as key tool for innovation creation and spreading, by
deploying the emergent paradigm of Open Innovation 2.0.
Design/methodology/approach – The study investigates the impact of clusters, or localised networks,
involving industrial, academic and institutional players, in the (bio)pharmaceutical setting; the aim is to
enrich the line of inquiry into cluster-based innovation by applying a social network analysis (SNA)
methodology, with the aim to provide new perspectives for recognising how the set of interactions and
relationships in the (bio)pharmaceutical context can lead to higher levels of knowledge transfer,
organisational learning and innovation spreading.
Findings – Starting from the top ten (bio)pharmaceutical companies, and the top ten contract research
organisations (CROs), the study helps understand that: the combination of the single big pharma company
and the CROs to which great part of the work is externalised, can be compared to a community of transaction
that deals with the supply and demand of a speciﬁc kind of goods and services; clusters can comprise either a
single one or more communities of transaction; virtual CROs act as a community whose all components
participate to the creation of value (co-creation), thus comparable to a certain extent to a community of
fantasy.
Originality/value – Based on the novelty of the OI2/SNA combination approach to deal with the
“complex” (bio)pharmaceutical industry, the outcomes of the present study mean to highlight: a
comprehensive perspective for understanding the dynamics of modularity and their implications for
innovation networks; the presence of innovation networks as main mean to promote and support paths of
knowledge creation and transfer.
Keywords SNA, Clusters, Open innovation 2.0, (Bio)pharmaceutical sector, vCROs
Paper type Research paper
Introduction: shifting from OI to OI2
Innovation is a process both based on inspiration, as expressed by inventiveness, and on
perspiration, as expressed by the number of people and time expended to achieve the ﬁnal
product (Levirs, 2014). In Schrage’s (2004) terms, innovation = invention þ adoption.
Innovation means, therefore, capturing a number of changes in ﬁrms’ approach to strategic
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management of technology, that have emerged over the years as a response to signiﬁcant
modiﬁcations in the competitive environment, e.g. increased dynamicity and turbulence, the
globalisation of markets and business activities, accrued competition (Gupta and Wilemon,
1996) and rapid advances in technology development (Bayus, 1994). In particular, these
changes include the end of the linear model of innovation (Ortt and Smits, 2006), ﬁrms’
increased reliance on external sources of technology (Chatterji, 1996; Roberts, 2001), their
enhanced attitude towards using multiple channels for technology exploitation
(Lichtenthaler, 2004) and the internationalisation of industrial R&D and innovation
activities (Teegen and Doh, 2002; King and Martinelli, 2005) . In response to these external
changes, companies have reorganised their innovation process becoming more open to the
acquisition and integration of information, knowledge and skills that come from outside
organisations, but are functional to their innovative strategies (Chesbrough, 2003;
Lichtenthaler, 2008). A process of disintegration of the vertical chain of assets and skills
necessary for innovation has, therefore, taken place, bringing to the afﬁrmation of the
paradigm of open innovation (OI), through which companies begin to acquire ideas and
technologies from outside and, at the same time, exploit their ideas to other companies and
technologies unused. In other words, OI can be deﬁned as “the use of purposive inﬂows
and outﬂows of knowledge to accelerate internal innovation and expand the markets for
external use of innovation, respectively” (Chesbrough and Crowther, 2006).
The following step in the evolution of this paradigm is based on principles of integrated
collaboration, co-created shared value, cultivated innovation ecosystems, unleashed
exponential technologies and extraordinarily rapid adoption and goes under the name of
open innovation 2.0 (Figure 1). For EU’s Open Innovation Strategy and Policy Group
(OISPG: European Commission, 2014, 2016), the OI2 paradigm is an innovation model based
on extensive networking and co-creative collaboration between all actors in society,
spanning organisational boundaries well beyond normal licensing and collaboration
schemes. Its characteristic is the use of a “quadruple helix model” where government,
industry, academia and civil participants work together to co-create the future and drive
structural changes far beyond the scope of what any one organisation or person could do
alone. This quadruple helix innovation approach is most successful when there is a shared
vision and shared value is created. The development of this approach clearly reﬂects the
perception that the innovation process has evolved, moving from vertically integrated
companies to companies large and small that play an active role within a network (Langlois,
2003).
The constant progress of the OI paradigm is tied to the multiple variations affecting the
surrounding environment, amongst which it has to be mentioned the need to involve as
Figure 1.
The evolution of
innovation
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many people as possible within the innovation process, as well as the importance of support
from ICTs, that play as a ﬁrst rate factor of cooperation between subjects (Marino and
Tamburis, 2005). A central role is then played by the concepts of value and shared vision:
corporations change their logics, shifting from a small-period optimisation of ﬁnancial
performances, to the pursue of a broader optimisation of both internal performances and
social conditions – that is, the creation of value for the social context the corporation lives in.
Speaking therefore of OI 2.0 (OI2, from now on) means the search for a new organisational
logic, based on principles such as: integrated cooperation, innovation ecosystems implying
the participation of multiple actors within the innovation processes, rapid adoption and use
of technologies able to generate high performing values, thanks to which the traditional
“borders” between activities fade out (Song et al., 2009), and the creation of networking
between innovators and the surrounding environment becomes possible. Similarly, the
existing gaps between lab researchers, R&D activities and the ﬁnal users, are overcome, in
favour of an easier andmore effective “open cage” of interactions.
It is important to note that OI2 (as was OI in the ﬁrst place) does not propose a strategy of
working with external parties; instead, it is about leveraging internal R&D. OI2 encourages
companies to expand their pool of resources to achieve their growth objectives. Such
phenomenon has mainly taken place in sectors characterised by complex innovative
processes and long lead time, as in the case of the (bio)pharmaceutical industries, which use
the advancement in information technology to make the innovation initiatives multilateral
in nature: this involves multiple actors from all over the world making the innovation
network boundary more porous. Pharmaceutical biotechnology is a relatively new and
growing ﬁeld in which the principles of biotechnology are applied to the development of
drugs. A majority of therapeutic drugs in the current market are bioformulations, such as
antibodies, nucleic acid products and vaccines. Such bioformulations are developed through
several stages that include: understanding the principles underlying health and disease; the
fundamental molecular mechanisms governing the function of related biomolecules;
synthesis and puriﬁcation of the molecules; determining the product shelf life, stability,
toxicity and immunogenicity; drug delivery systems; patenting; and clinical trials (Mallela,
2010). This means that ICTs push towards the OI2 paradigm by providing them with more
ﬂexible approaches to the innovation, allowing therefore a greater integration between
traditional and innovative services and products, and eventually shifting from an
innovation decided and driven from few high-qualiﬁed subjects, to an innovation born from
multiple and multidisciplinary skilled actors. Thus, users are no longer seen as passive
receptors, but as active parts of the innovation process, or better a value co-creator. It is easy,
therefore, to conclude that the more the connectivity and networking dimensions increase,
the more the users will be called to act as value co-creators, with high expectations (Curley
and Formica, 2013).
The objective of this paper is to demonstrate how new forms of organisation (CROs:
contract research organisations) that arise in the big pharma ﬁeld in response to these
changes are intended as development platforms for innovation, especially considering that
their synergistic combination with the use of ICTs determines the transition from real forms
to virtual forms of organisation (vCROs) able to spread innovation more quickly and make
more lasting effects. In particular, the present work intends to investigate the impact of
clusters, or small worlds – i.e. localised networks involving industrial, academic and
institutional players: D’alise et al. (2014), Giustiniano and D’Alise (2015) – of vCROs in the
(bio)pharmaceutical setting; the aim is to enrich the line of inquiry into cluster-based
innovation by applying a social network analysis (SNA) methodology, with the aim to
provide new perspectives for recognising how the set of interactions and relationships in the
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(bio)pharmaceutical context can lead to higher levels of knowledge transfer, organisational
learning and innovation spreading: this makes possible to study how (bio)pharmaceutical
companies have organised over time to exchange technologies and pieces of knowledge with
different classes of external organisations (e.g. universities, competitors) along the different
stages of the R&D and innovation development process (e.g. drug discovery and drug
development), in accordance to the fundamental principles on which the OI2 paradigm is
based.
Innovation networks ecosystems in the (bio)pharmaceutical industry
High-technology industries with their rapidly developing innovation and knowledge base
serve as an important source for national economies. In such a dynamic and competitive
industrial environment, no single ﬁrm has the ability to keep pace with the growing
scientiﬁc and technological progresses without external partners (Cantner and Rake, 2011).
This is particularly true for pharmaceutical research and development (R&D), remained a
sequential and insular process for the most part of the past 50 years (Getz and Kaitin, 2012),
a situation that – by the way – stands amongst the triggers of a major decline in R&D
productivity in the industry during the ﬁrst decade of the twenty-ﬁrst century, as widely
documented (DiMasi et al., 2003; Munos, 2009). The adoption of an initial OI perspective in
the high-tech sector of pharmaceutical biotechnology has, therefore, represented a new R&D
model that holds great promise in transforming the drug development process by
integrating capabilities and expertise amongst a diverse collective of internal and external
stakeholders. The creation of a tight inter-ﬁrm network of R&D collaboration has become an
unavoidable strategy for innovative companies (Chiaroni et al., 2008; Roijakkers and
Hagedoorn, 2006; Salman and Saives, 2005) and, as a result, the sector has witnessed a
sharply increasing frequency and typology of inter-ﬁrm partnerships between large
established pharmaceutical ﬁrms and a range of biotechnology companies (Hagedoorn and
Roijakkers, 2002; Powell and Grodal, 2005; Rothaermel, 2000), successfully creating a track
for high-technology companies to achieve progress in knowledge and innovation
(Roijakkers, 2003). The R&D network formation grounds on the choice-based perspective
that is emphasised in the network theories: from this view, the cooperation between
pharmaceutical companies and biotechnology ﬁrms is based on their reciprocal interests to
the extent of their complementarities. Such network cooperation has become a “small world”
to the extent that vast numbers of ﬁrms with different national origins were all connected to
each other, which consequently has globalised the world market in the high-technology
sector (Krogmann et al., 2013). This offered pharmaceutical biotechnology ﬁrms various
opportunities to increase their efﬁciency of R&D efforts, reduce their cost and risk investing
in the launching R&D projects and create options for knowledge and innovation
development. In many cases, partnerships have been created with academic research
centres, thus providing an important mechanism for gaining access to cutting-edge science
and new technologies, whilst allowing the company to lower overhead and investment in
expensive discovery tools and technologies (Kaitin, 2011a). It is, for instance, the case of
Pﬁzer’s newly created regional Centres for Therapeutic Innovation and Eli Lilly’s
Innovation Fellowship Awards Programme that represent those companies’ commitment to
academic–industry partnerships, whose goal is to bridge the gap between basic research
discoveries and the commercial development of new medicines (Getz and Kaitin, 2012). The
importance of academic alliances has resulted in a geographic re-centralisation of the
remaining in-house R&D hands-on activities close to the centres of academic excellence
(Boston, Cambridge and Oxford). Lab-based R&D facilities have been replaced by virtual
research and project management units to collect and preserve the scientiﬁc expertise in the
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therapeutic areas of interest (AstraZeneca, Neuroscience iMed, Cambridge, MA, USA) (Raja
and Sambandan, 2015).
Contract research organisations
The value chain of the pharmaceutical industry is complex, highly dependent on policies for
drugs approval and increasingly disaggregated, with big pharma collaborating in different
ways with smaller actors (Raja and Sambandan, 2015). To this end, the acquisition of OI2-
based principles has consolidated the importance and expansion of outsourcing which, in
turn, has set as a source of business opportunities seized by the industry: it is the emergence
of companies that provide services related to research in the clinical/(bio)pharmaceutical
ﬁelds and which are known as CROs. They are distinguished from the clinical research
organisations – with which they share the acronym – that manage and perform mostly
activities related to clinical studies, and that, as such, should be rather considered as a
subset of the CRO. In the overall, CROs provide support primarily in activities related to the
central phase of clinical trials of (bio)pharmaceuticals or diagnostic medical device, in
particular: study design, drafting of the medical protocol, selection of clinical sites involved,
enlisting of patients, site monitoring, data collection and analysis of the results by means of
parametric biostatistics. In the latter cases the term CRO, as seen, is also interchangeably
used as an acronym for organisation of clinical research (see Figure 2).
More in general, CROs provide specialised services by means of business modalities that,
although customisable according to the requirements of the company, can be summarised in
three main organisational forms (Figure 3):
Figure 2.
Drug development
value chain
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 FIPCo (fully integrated pharmaceutical company): traditional model of the vertically
integrated pharmaceutical company;
 FIPNet (fully integrated pharmaceutical network): the companies move away from
the traditional model, ﬁlling the gaps through partnering. The FIPNet enables the
creation of a network through three lines of action: outsourcing (Level 1), OIed R&D
(Level 2) and corporate venturing (Level 3) (Raja and Sambandan, 2015); and
 VIPCo (virtually integrated pharmaceutical company): a fully disintegrated but vital
company, as it outsources/contracts extensively for services at any point (s) in the
value chain, providing access to complementary assets outside the ﬁrm. This allows
the company to maintain control of the product development process and defer the
point at which they plug into the value chain.
Virtual communities and virtual contract research organisations
A virtual community creates value when it can effectively meet four basic elements: a
speciﬁc interest, relationships, entertainment and a commercial exchange. This allows to
draw the bounds, although purely theoretical, between three different categories of
communities, namely: communities of transaction, interest and fantasy:
 The communities of transaction have the same aim to facilitate the matching of
supply and demand of goods and services and to provide the necessary range of
information useful to the realisation of such exchanges. They represent a new kind
of intermediary, a trader able to attract a critical mass at the site of suppliers and
customers to facilitate the performance of transactions (Hagel and Armstrong,
1997).
 The communities of interest arise instead from sharing a passion, an opinion, an
activity amongst community members. They pursue the goal of providing speciﬁc
information services to help participants to acquire or to deepen knowledge on the
topic of interest and develop interpersonal relationships. The ability to exchange or
buy products constitutes an additional service and possible.
 The communities of fantasy are instead places devoted to leisure where often you
wear the clothes of ﬁctional characters and so participate in interactive games. The
true ability to create value for the community today lies in being able to develop
both the social dimension and the economic one, i.e. to pursue a strategy of
“integration”. The vertical communities are not only located into electronic markets
in which each user, exploiting the information, potential of new technologies,
Figure 3.
Vertical
disintegration from
FIPCo to FIPNet to
VIPCo
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research to lower costs and the counterparty into transactions, but rather
encompass a space in which the community dimension is vital in the process of
value creation. The ﬁduciary component plays a fundamental role in the
transactions. The high capacity of organisation and control of transactions is
combined with an equally valid knowledge management entered and spread
throughout the network. These two elements allow a virtual system to achieve good
results in terms of participation of users in relation to the different services that are
offered (Bonacci, 2007).
All this brings out the various beneﬁts that an enterprise can draw from access to a virtual
community: ability to greatly expand the effectiveness of its action and communicative than
working in isolation in the network; reducing time and costs associated with the research
and identiﬁcation in the global dimension of electronic networks. Virtual communities can
provide a valuable opportunity to beneﬁt from the advantages offered by new technologies
in terms of effectiveness and efﬁciency in the implementation of transactions, but also for
exchange of knowledge and innovation (Bonacci, 2007).
The development of vCROs, as organisations comprised of autonomous communities of
scientists and service providers, managed by a central source of capital and leadership, and
engaged in open and coordinated collaboration, is a good example of new opportunities
seized by the (bio)pharmaceutical sector in the light of the above described changes. Sector
enterprises have become aware of the impossibility – in terms of cost and time – to possess
internal knowledge, as well as the necessary competencies for all stages of the drug
development value chain, so they have seen in outsourcing the best strategy to stay
competitive and be on the market. The spread of the model of vCROs and offshoring is also
because of another important element in the innovation process concerning CROs, that is the
ongoing digital revolution in the pharmaceutical sector, which can be identiﬁed in three
main strands (Kaltenbach, 2014; Sundgren, 2014; Parek et al., 2016):
 e-clinical: refers to the deployment of technologies such as electronic data capture,
clinical trial management systems or randomisation and trial supply management
systems, commonly using interactive voice response systems, electronic patient
diaries and other applications);
 e-marketing: such concept can be in turn divided into three categories: end user
(including doctors and hospitals), mostly based on providing reports, scientiﬁc data,
etc. to the specialists to start the promotion of a new drug; bulk drugs, not visible to
the end users and mostly involving established drugs like antibiotics, antipyretic,
etc.; API (active pharmaceutical ingredients) as pure B2B declined within the (bio)
pharma sector; and
 e-health: also in this case, more than one scenarios can be considered: e-health services
to enhance disease models and biomarkers (the clinical programmes are seen as a real-
time interaction patient evaluation that allow much more information to be captured
than the “traditional” clinical trials. Furthermore, the diagnostic tools are supported by
sophisticated re-use and data mining of health information from EHRs and other record
systems); improving clinical study design by e-health services (re-using of EHR data by
the project team during the study design and protocol development; enabling a network
of hospitals to precisely identify the patients in its EHR repository who match an issued
protocol, for ﬁner-grained examination of these patients’ EHR against the protocol).
The switch to a virtual drug discovery model can retain the potential to promote scientiﬁc
innovation and drastically reduce the costs of drug research, actually addressing two of the
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major challenges facing the industry in a single stroke. As a consequence, CROs ﬁt now in a
virtual R&D scenario in which the core expertise of pharmaceutical companies is
progressively shifting to develop, through a number of different disciplines, the networking
capabilities and partnering, or to interact with virtual organisations and combine all the
resources at available to enhance the process, the product and the company as a whole. In
this context, an effective outsourcing has precisely the role to make continually skills, ways
of thinking and innovative forms of organisation, not always present in many companies.
CROs become, therefore, a platform that can be deﬁned of net-sourcing, in which to create a
network of partnerships and skills that meet the needs of all possible stakeholders, up to the
patient/end-user, who can take advantage of a product/service innovative, effective and
personalised.
In virtual organisations, the network makes it possible to keep an agile enterprise design,
yet capable at the same time of pro-respond to change and reduce the variability of the
results. Potential sources of risk still exist and are linked to the signiﬁcant tangible and
intangible resources put together amongst networks and each other interdependent. The
dependence, as previously highlighted, can, in fact, be a source of risk, but it also works as a
driver of proﬁt sharing, given that the network is determined by the contribution of each
partner to the project. The vCROs offer, therefore, a comprehensive platform of possibilities
collaboration that a partner may have available for the search process and development of a
given product: the strength of the CRO is to coordinate and optimise the entire study based
on an end-to-end partnership model, also known as a one-stop shop. The company’s main
task remains the creation of value, and then the monitoring of the entire process, ensuring a
fair exchange between partners, as well as good communication and high transparency.
This minimises the ﬁxed costs for infrastructure and staff, producing value in a shorter time
and, consequently, a faster return on investments.
Research problem
The acquisition of the OI2 model has consolidated the importance and expansion of
outsourcing causing the emergence of the vCROs, as new wave of the dynamics of
innovation transfer, capable of enabling the translation between scientiﬁc and technological
discoveries and information, gaining access to new business opportunities.
Starting from these premises, the paper aims at investigating the clusters of vCROs as a
speciﬁc form of alliance, in the setting of the pharmaceutical industry, and its impact on
innovation. Clusters have become a prevalent form of industrial organisation, and their
innovativeness is considered to be a key source of regional and national competitive
advantage. The work tries to analyse some aspects concerning the effects of networks on
clinical research. Clusters are localised networks (Curzio and Fortis, 2003), territorial
aggregations of different players, that usually arise when business segments require high
levels of specialisation from multiple contributors (Ghadar et al., 2012). They can have a
more or less formalised structure and, in any case, they assume a network conﬁguration
through contractual mechanisms.
As seen in Figure 2, the pharmaceutical R&D process is organised as a strict sequence of
different stages that are better performed through the involvement of different players
assuming different roles in the healthcare value chain (e.g. research, manufacturing,
provision of care and regulation). In such a context, organisations often decide to work on a
multiplayer basis to speed up the multistage process of pharmaceutical research through the
sharing of scientiﬁc knowledge and the division of labour and the inclusion of patients in
clinical trials, to foster enrolment and the fulﬁlment of protocols. Interactions between
complementary players, who have different roles in the value chain, are, therefore, needed
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for innovation. Firms must deal with the new systemic dimensions of technology and
research. Nonetheless, the progressive standing out of virtual vertical model business,
because of the intrinsic difﬁculty of generating an equal value creation in each part of the
value chain, has driven us to adopt the “small world” concept, as introduced by D’Alise et al.
(2014) meaning highly dense clusters or hubs randomly connected to other clusters or hubs by
weak ties in a sparse structure. The reference to this kind of structure allows us to deal with
the literature on clusters and networks theoretically in manyways.
To this end, the adoption of the SNA ﬁts with the research objective: assuming in fact
that the relationships occurring between actors are held to actors’ roles inside a network
(Cross and Parker, 2004; Meneguzzo and Cepiku, 2008), the whole set of nodes/actors (with
their peculiar features) and the set of ties (e.g. connections, relations and/or interactions for
the exchange of resources) give origin to a social network (Powell, 1990) that can be can be
articulated on different levels: interpersonal (a single person belonging to an organisation),
intra-organisational (a speciﬁc people group within an organisation), inter-organisational (a
set of relations existing between organisations). In this case, SNA is meant to analyse inter-
cluster network characteristics and their impact on the cluster’s innovative performance,
overcoming the limits of the absence of signiﬁcant contributions examining clusters of
clusters, by using appropriate sets of indicators and graphic instruments. Moreover, the
present work intends to contribute to the literature debate on the network structure as most
beneﬁcial for innovation: a small world network structure could provide an intermediate
solution between sparse and dense (i.e. “virtual”) structures that are complementary, trying
to establish its connection to innovation outputs.
Accordingly, the research questions can be summarised as follows:
RQ1. What is the “shape of the bridge” between OI and virtual organisation forms in the
light of the small-world network structural characteristics?;
RQ2. How can clusters stand as answer to innovation transfer issues?
Analysis
We explored the arguments mentioned in the previous sections by using a social network
approach (Bonacci and Tamburis, 2015) applied to the worldwide pharmaceutical industry.
We started our research by listing the top ten pharmaceutical companies and the top ten
CROs (Table I).
With the help of reliable sources like the US Cluster Mapping Database, or ﬁrst rate
website (e.g. www.pharma-iq.com or www.centerwatch.com), online libraries, newspapers
Table I.
Top ten world-wide
pharma companies
and CROs 2017
(classiﬁed by
revenue)
# Pharmaceutical companies Contract research organisations
1 Pﬁzer Quintiles
2 Merck Parexel
3 Johnson and Johnson Covance
4 Roche PPD
5 Sanoﬁ Icon
6 Novartis PRA Health Sciences
7 Abbvie INC Research
8 Astra Zeneca Charles River Laboratories
9 Gilead Chiltern
10 Amgen SGS
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and archival data (ofﬁcial documents, previous studies on clusters), we managed to identify
some amongst the most valuable relationships between companies and CROs, as well as
some amongst those between companies, CROs and surrounding academic and institutional
organisations. With reference to the already mentioned Pﬁzer's and Eli Lilly's initiativers, in
both cases the organisations are comprised of autonomous communities of scientists and
service providers, managed by a central source of capital and leadership, and engaged in
open and coordinated collaboration: this strategy has been recently adopted because of the
beneﬁts that out-licensing provides under certain circumstances (Getz and Kaitin, 2012; Raja
and Sambandan, 2015). It is also the case of the “virtual company” Bio Data Bridges (www.
biodatabridges.com/Clientel) that works as an external contractor for some amongst both
the pharma companies and the CROs reported in Table I.
In regard instead to Astra Zeneca's mentioned research and management policies, this
ﬁts in particular with its main marketing processes, focused on transforming doctors into
business partners before creating effective work instruments so that the process owner is a
medical science liaison (Goncharuk and Getman, 2014).
Using the UCINET VI software (Borgatti et al., 2002) an “n x n” sociometric matrix was
drawn in the ﬁrst place reporting for all the rows and the columns all the entities above
described; a weight (going from 1 to 7) was then assigned for each cell according to the
strength of the connection. In particular, the cells corresponding to the same entity on both
the row and the columns were not considered (each entity is of course completely connected
with itself). The cells corresponding to connections for which no information was gathered
were as well left blank. The following cluster analysis resulted in 20 different clusters of
companies, CROs and their surrounding industrial, academic and institutional
organisations; amongst these, six clusters were selected as they featured similar number of
nodes, spanning between a minimum of 114 and a maximum of 133, signiﬁcantly higher
than the number of nodes showed by the other clusters. As for the attributes to highlight, we
considered:
 the nodal characteristics: for each node in the clusters, we identiﬁed the type of
organisation, in particular the role in the vertical chain (whereas it was possible to
sketch a precise vertical chain). We obtained different categories for the ﬁrm type
(e.g. biotechnology, pharmaceutical, academic institution, etc.) and the states in
which the ﬁrms are located. We used the sources mentioned above; and
 The cluster’s characteristics: the number of employees and the cluster’s
specialisation (from the US Cluster Mapping Database).
As for the relational data, the study of the marketing strategies of the mentioned ﬁrms
(as previously suggested) made possible to investigate into the transactions and
agreements between the nodes of the cluster related to R&D, so to highlight short-range
intra-cluster and long-range inter-cluster ties. Intra-cluster ties are ties between the
nodes belonging to the same cluster, whilst inter-cluster ties are ties between nodes
belonging to different clusters. One node can be simultaneously in different clusters,
and this is another case of an inter-cluster tie (even if the tie will occur between two
divisions of the same ﬁrm).
As the focus is on the impact of the ties on a ﬁrm’s innovative performance, we
ﬁltered the output to keep just the alliances of selected types, namely R&D agreements
and manufacturing agreements. Thus, using NetDraw, a tool from UCInet suite, a
visual representation of our big pharma “Small World” network comprising the
selected six clusters was constructed. In the table, the long-range, inter-cluster ties are
summarised: each of the six clusters is connected to external clusters through
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the linkages of its nodes to other clusters’ nodes; the width of each segment represents
the strength of the connection as a function of the number of ties. In this way, we
reconstructed both the whole network and the single sub-units of the network, which
are clusters. Along with it, some amongst the most important quantitative measures for
use in the SNA were developed, i.e. network cohesion (density: a measure of the relative
number of connections; standard deviation: a measure of the variability amongst the
whole set of connections of the sociogram) and network centrality (network
centralisation index: measures the degree to which a network approaches a perfectly
symmetric or “star” network). The cliques analysis then worked out the main amongst
the possible “high density subgroups” derivable from the network breakdown. Such
elements are showed in Figure 4.
Results and discussion
OI relies on a ﬂexible, coordinated and integrated community of internal and external
stakeholders, each contributing unique competencies and energies. These partnerships also
rely on leading-edge technologies to create collaborative working environments and to share
data, governance and operating procedures and risk (Hunter, 2010). To this purpose, what
emerged from the analysis of the data retrieved is that the combination of the single big
pharma company and the CROs to which great part of the work is externalised, can be
compared to a community of transaction that deals with the supply and demand of a speciﬁc
kind of goods and services (Figure 5). Moreover, as the single CRO can cooperate at the same
Figure 4.
Big pharma “Small
World”Network and
main SNA-related
properties
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time with more than one company, it can be, therefore, stated that CROs create intra- and
inter-cluster communities of interest, as they share a speciﬁc task within the wider
community of transaction (porous inter-ﬁrm R&D network boundaries); this implies in the
ﬁnal analysis that a cluster can comprise either a single or more than one communities of
transaction.
As Figure 4 shows, in the ﬁrst place, the quasi-star-like sociogram of the network makes
clear the good level of network cohesion (> 80 per cent density and< 40 per cent deviation)
(Cordaz, 2005). Besides that, all the clusters are central to each other (in terms of betweenness
centrality), although the cliques analysis suggests that clusters 12 and 15 show a slight
greater rate of outcloseness. As hereafter explained, such properties somehow reﬂect on the
possibility to provide answers to the research questions.
RQ1 investigated the impact of the small world network structural characteristics on the
cluster’s innovation output. According to D’Alise et al. (2014), the integration of the short-
range clustering and the long-range reach was considered to have a positive impact on the
cluster’s innovative output. As for our research, CROs being a platform of net-sourcing
(Lukensmeyer and Torres, 2008) means that they have become able to somehow “upgrade”
the drivers that lead companies to the outsourcing choice, thus achieving:
 an over-accelerated time to market, a critical factor in the drug development process;
 a glocal dimension of improvement, meaning helping the development process by
means of a tailored mix of knowledge deployment on local level and project
management on global level; and
 an increasingly rapid access to advanced technologies, which minimises times and
costs related to purchasing, installation and staff training.
If an OIed R&D network granted to large pharmaceutical companies to successfully
undergo the challenges of technological innovation during the so-called “biotechnology
evolution” and keeps their dominant position in the high-tech industry (Chiaroni et al., 2008),
the improved collaboration with a new kind of external actors (e.g. academic research
Figure 5.
Pharma companies
and CROs as
members of
communities of
interest and
transaction (on the
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right)
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centres) has set into motion an OI2ed R&D network cooperation based on the mentioned
“quadruple helix model” of innovation to drive changes far beyond the scope of what any
one organisation can do on their own (Curley and Salmelin, 2013). The result has been the
rising of a further network of externalisation (virtualisation) of the productive processes,
especially for (but not limited to) CROs, as they deal with the great part of the drug
development value chain, for which opportunities have arisen to increase their efﬁciency of
R&D efforts, reduce their cost and risk investing in the launching R&D projects and create
options for knowledge and innovation development (Gottinger and Umali, 2008).
An overlap between two peculiar phenomena has, therefore, occurred: on the one hand,
the single CRO that builds a network of cooperation with more than one big pharma
company; on the other hand, surrounding industrial, academic and institutional
organisations that build networks of cooperation with both companies and CROs. The
emerging virtual entity was already introduced as “comprised of autonomous communities
of scientists and service providers, managed by a central source of capital and leadership,
and engaged in open and coordinated collaboration” and, as a matter of fact, acts as a
community whose all components participate to the creation of value (co-creation), thus
comparable to a certain extent to a community of fantasy (Figure 6).
Virtual outsourcing stands then as a means of bridging networks between clusters: this
kind of organisational model pushes towards the deverticalisation of the bio-pharmaceutical
sector on the whole, allowing the increasing of strategic alliances between big- and small-
sized companies, as well as between companies and research institutions, favouring the
information ﬂowing in spite of shorter innovation cycles, industrial R&D’s escalating costs,
as well as dearth of resources (Enkel et al., 2009). Inside a vCRO, the transfer of knowledge
becomes much more easier, so innovation can stem (and spread) more effortlessly, as it hosts
an integrated partnership that spans the entire R&D continuum – from drug discovery
through development and commercialisation of new medical therapeutics. Large
pharmaceutical companies provide resources, regulatory experience and infrastructure (e.g.
scale manufacturing, marketing and sales); surrounding research centres supply basic and
translational research capabilities and access to cutting-edge science; small pharmaceutical
and biotechnology companies provide innovative discovery and early development
capabilities; CROs and investigative sites deliver clinical research operating and execution
capabilities; and patient groups help set the research agenda, provide access to study
volunteers and, in some cases, contribute research funding (Kaitin, 2011b). This allows to
answer RQ2: whereas traditionally, innovation was conceived as mostly transferred from
hubs (out-degree centrality) towards peripheral actors or intermediaries, often big
pharmaceutical companies or incumbent biotechs, the virtualisation sheds light on the
phenomenon of the “strength of weak ties” (Granovetter, 1973): if resorting to the
virtualisation means (amongst the rest) optimising the entire production process according
to an end-to-end partnership model, the sum of n ties, besides the different extent of
weakness (or strength?), causes high-density clusters that can bear localised phenomena of
Schumpeterian radical innovation. This is, in turn, transferred through waves of gradual
intensity, thanks to the creation of networks modelled by a “global sustained innovation”.
This also means that the lack of a sole central actor in favour of a (virtual) multi-central
structure eventually shifts the idea of coopetition (which emphasises simultaneously
cooperative and competitive behaviour amongst organisational units: Tsai, 2002) to a far
upper level that also implies (as community of fantasy) a collective use of shared knowledge
to pursue common interests.
Networks of connections are innovation, but also production systems that inﬂuence
global product performance: strong linkage between innovation and emergence of network
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structures thus exists, supported particularly by recent evolutions regarding the mentioned
scale-free models of alliances (deverticalisation) (Gay and Dousset, 2005).
Conclusions
The main contribution and results of the study were to introduce a ﬁrst attempt of an “Open
Innovation 2.0/Social Network Analysis” combination approach for the analysis of the
“complex” pharmaceutical industry, enriching the line of inquiry into cluster-based
innovation, and providing new perspectives for recognising how the set of interactions and
relationships in the pharmaceutical context can bring to higher levels of knowledge transfer,
organisational learning and innovation spreading. Based on the literature that shows an
increasing importance of network structures and the increasing amount of international
research collaboration in pharmaceuticals, we explored differences in collaboration patterns
on the country level in different areas of (bio)pharmaceutical research and their
developments over time. We used the SNA to visualise collaboration networks and to
calculate network statistics for different disease groups. Moreover, we analysed endogenous
network dynamics, i.e. mechanisms within the network that are responsible for new
connections being build up or existing ones being cut off. Inside such processes, the
importance of the users increases, too. This approach was based on the premise that
individuals are inﬂuenced by direct and indirect exposure to other person’s attitudes and
behaviour; by access to resources through the network; and by the individual’s location in
the interpersonal network. In particular, we tried to implement the impact of a cluster’s
small-world network structural characteristics as well as of nodal characteristics on the
cluster’s innovative performance. Addressing with such approach, the potentialities of the
CROwithin a “Virtually Integrated pharmaceutical company” organisational model allowed
us to highlight:
Figure 6.
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 a comprehensive perspective for understanding the dynamics of modularity and
their implications for innovation networks; and
 the presence of innovation networks as the main mean to promote and support
paths of knowledge creation and transfer.
A cooperation network between ﬁrms is not distinct from a social network between people.
Innovative approaches in co-creation of value can in fact turn into innovatice approaches in
co-creation of care (Brenner et al., 2018). Globalisation makes the world narrow and small,
and the distance is no longer an obstacle for the connections. Furthermore, integrating into
such a research network enables high-tech ﬁrms to optimally share the resources that they
possess. As a result, they would have opportunities to access the resources available in the
whole world and exchange technological and innovative information with greater facilities
(Krogmann et al., 2013).
The peculiarity of the suggested approach offers room for improvement; the structure
itself of innovation outcomes and transfer needs to be tested because, as pointed out
elsewhere (Hoyer, 2011; Bonacci and Tamburis, 2016), weak and strong ties between
companies and employees increase the social capital and contribute to information exchange
and problem-solving solutions within an innovation value chain.
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